China drug sector probe widens as officials visit Novo site
COPENHAGEN/LONDON (REUTERS) - Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk A/S, the world's biggest maker of insulin, the latest evidence of a widening investigation into Western drugmakers.
A Chinese newspaper also reported an allegation from an unnamed person that Sanofi SA of France had paid around 1.7 million yuan (S$351,475) in bribes to hundreds of doctors in China in 2007, a claim Sanofi said it took "very seriously".
The latest developments suggest Chinese investigations into bribery and over-pricing, which have so far centred on Britain's GlaxoSmithKline Plc (GSK), may have a wide impact across the pharmaceuticals industry.
Novo said on Thursday that local Administration for Industry and Commerce (AIC) officials visited a production facility in Tianjin on Aug 1, adding that there had been no visit at the company's head office in the country.